News
Sarepta plunges
Digest more
The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...
While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
1d
GlobalData on MSNSarepta Therapeutics to cut 500 jobs amid restructuringThe company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.
Explore more
The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.
These were the most active stocks ahead of Friday's market open: Sarepta Therapeutics Inc.'s stock tumbled 27% after the company said another patient died following gene-therapy treatment, Bloomberg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results